A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.
Also called NCT03358030
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 213 participants
- Sponsor
- Registry
-
NCT03358030 -
2017-002165-21
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT03358030. Randomized; quadruple masking; primary purpose prevention. Start 2017-12-26 (actual); primary completion 2019-07-10 (actual). Results posted on 2023-01-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
- Acronym
- EMERALD
- Condition
- End-stage Renal Disease (ESRD)
- Intervention (Drug)
- ISIS 416858
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct03358030- Content hash
362d0511b1c57affb4b7016d1438086d3b230266ec09a404d9e5ffb685c4294b